Optimizing Treatment of Patients with Co-Existing Cardiorespiratory Pathology by Administration of Anti-Inflammatory Roflumilast and Cardioprotective Agent Quercetin

The article discusses the research findings on the effectiveness and safety of combination treatment with roflumilast and quercetin in aggravated chronic obstructive pulmonary disease (COPD) along with a co-occurring comorbid ischemic heart disease (IHD). Clinical evidence highlights the effect of combination of roflumilast and quercetin as a part of the basic treatment of COPD and conventional treatment of IHD on clinical symptomatology, C-reactive protein levels, and α2-macroglobulin in plasma. It was found that a complex therapy leads to a substantial improvement of patients’ clinical condition owing to reduced systemic inflammatory activation and improved immune defense, which decreases incidence of cardiovascular complications.